Tuberculosis (TB) is caused by a bacterium called Mycobacterium tuberculosis. The bacteria usually attack the lungs, but TB bacteria can attack any part of the body such as the kidney, spine, and brain. Not everyone infected with TB bacteria becomes sick.
Tuberculosis (TB) is a bacterial infectious disease caused by Mycobacterium tuberculosis. It primarily affects the lungs (pulmonary TB) but can also affect other parts of the body (extrapulmonary TB). TB is a serious global health concern due to its contagious nature and potential to cause severe illness and death if left untreated.
Prarthana Hospital & Research Centre is a leading institution in the diagnosis and treatment of tuberculosis (TB), a contagious bacterial infection that primarily affects the lungs. Their dedicated team of pulmonologists, infectious disease specialists, and microbiologists employ cutting-edge diagnostic methods, including sputum tests and imaging, to accurately diagnose TB.
Prarthana Hospital offers comprehensive TB treatment programs that typically involve a combination of antibiotics over an extended period. They prioritize patient education, adherence to treatment, and close monitoring to ensure successful recovery and prevent the spread of TB. With a commitment to eradicating this global health threat, the hospital provides expert care, support, and resources for individuals affected by TB.
First-Line TB Drugs: The primary TB treatment regimen consists of a combination of first-line drugs that are highly effective against the bacteria. The standard regimen typically includes four drugs:
a. Isoniazid (INH): This medication targets actively growing TB bacteria and is a cornerstone of TB treatment.
b. Rifampin (RIF): Rifampin is another critical drug that helps prevent the development of drug resistance.
Intensive Phase: During the initial two months of treatment, patients take all four first-line drugs (INH, RIF, PZA, EMB). This phase aims to kill as many bacteria as possible.
Continuation Phase: After the intensive phase, the treatment regimen may change. In many cases, patients continue taking INH and RIF for an additional four to six months to eliminate any remaining bacteria.
Directly Observed Therapy (DOT): TB treatment is typically administered under direct observation by healthcare providers or trained community health workers. This ensures that patients take their medications as prescribed and helps prevent the development of drug-resistant TB.
Monitoring: Regular monitoring of treatment progress is essential. Patients undergo clinical evaluations, chest X-rays, and sputum tests to assess the effectiveness of treatment and detect any drug resistance.
Treatment Adjustments: If drug-resistant TB is suspected or confirmed, the treatment regimen may need to be adjusted. Drug-resistant TB requires more specialized treatment with second-line drugs, which are often less effective and can have more side effects.
Adherence: Patients must complete the full course of treatment as prescribed by their healthcare provider, even if they start feeling better. Stopping treatment prematurely can lead to treatment failure and the development of drug-resistant TB.
Cure and Recovery: The primary goal of TB treatment is to cure the infection. With appropriate treatment, most individuals with TB can recover fully and lead healthy lives.
Improved Health: TB treatment helps individuals regain their health and reduce or eliminate symptoms such as coughing, fatigue, weight loss, and night sweats.
Prevention of Disease Progression: Without treatment, TB can progress and become more severe, potentially leading to complications, organ damage, and death. Treatment stops the progression of the disease.
Prevention of Transmission: TB is highly contagious through respiratory droplets. Effective treatment reduces the infectiousness of individuals with TB, reducing the risk of transmission to others.
Prevention of Drug-Resistant TB: Incomplete or inadequate TB treatment can lead to drug-resistant forms of the disease, which are more challenging to treat and can have a higher mortality rate. Completing treatment helps prevent drug resistance.
Reduced Mortality: TB is a leading cause of death worldwide, particularly among people with weakened immune systems. Treatment reduces the risk of death from TB.
Prarthana Hospital & Research Centre in Rewa is a leading institution for the diagnosis, treatment, and prevention of tuberculosis (TB). With a team of experienced pulmonologists, state-of-the-art diagnostic tools, and a patient-centric approach, we provide comprehensive care for individuals affected by TB. Our commitment to early detection, evidence-based treatments, and ongoing support ensures effective management, recovery, and control of this infectious disease.
Prarthana Hospital & Research Centre’s dedication to advancing TB care and providing compassionate healthcare makes us a trusted destination for individuals in the region seeking expert care for tuberculosis, offering hope, healing, and a brighter future for those facing this challenging condition.
Kraken Onion Market